A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

AI in Healthcare


Marshall Pillay joins OKRA

   by Marina Gonzalo    175
Marshall Pillay joins OKRA

Cambridge, UK, October 5th 2020 - OKRA is thrilled to announce the appointment of Marshall Pillay as VP Commercial - Europe and International. Starting today, Marshall will join OKRA from AKTANA, where he was most recently GM of Europe, responsible for all business and operations in the continent.

OKRA raises ambitious target to 6 million predictions in Life Sciences by end of 2020

   by Marina Gonzalo    140
OKRA raises ambitious target to 6 million predictions in Life Sciences by end of 2020

Cambridge, UK, September 29th 2020 - Following on from June's breakthrough news that OKRA hit its target of 2 million validated predictions at >95% accuracy a full 6 months early, the company has set its sights on a record-breaking 6 million predictions completed by year end. This means that pharma companies have benefitted from an unparalleled level of support during the most uncertain time in recent memory, using predictions to guide their staff to take the right next step. This is 1 million more than the revised target set only in June.

[Interview] Shaping European AI Regulation To Secure Global Leadership In Healthcare

   by Andrii Buvailo    729
[Interview] Shaping European AI Regulation To Secure Global Leadership In Healthcare

While the history of Artificial Intelligence (AI) field began in the distant 1950s, its practical value had largely remained limited all the way until the emergence of powerful hardware (GPUs) in the late 1990s. Other complementary technologies played an important role in the AI progress too: new data storage capabilities, cheap cloud infrastructures, advanced deep learning algorithms -- all these things became reality only in the 21st century, effectively setting AI field for exponential development trajectory and commercial practical utility. 

Today AI tech has matured to an extent it has become a strategic factor, a competitive differentiator, not only for individual companies but for the whole industries and countries. Needless to say, healthcare -- one of the major industries -- is an important end-user of AI technologies. Countries that care to adopt AI in their healthcare strategies today will have major competitive benefits for public health and safety tomorrow.

Aigenpulse introduces novel data intelligence platform to life science markets

   by Alice Chamberlain    334

Life science and data technology innovator, Aigenpulse, is introducing a new state of-the-art data intelligence platform which is designed to expedite the drug discovery and development process. The Aigenpulse platform harnesses the latest artificial intelligence and machine learning tools to deliver advanced analytics to underpin scientific decision making.